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AnessentialfunctionofboththeAssociationforAppliedPsychophysiologyandBiofeedback
(AAPB) and the Society for Neuronal Regulation (SNR) is the systematic evaluation of
psychophysiological interventions that have been developed for the treatment of medical
and psychiatric disorders. In order to address scientiﬁc concerns regarding the efﬁcacy of
speciﬁc clinical applications of biofeedback, these two societies formed and Efﬁcacy Task
Force.Theprocesstobeusedintheassessmentoftreatmentefﬁcacy,speciﬁcityandclinical
utility is presented in the form of a template that will serve as the foundation for a series of
scientiﬁc reviews and practice guidlines to be published by both societies.
KEYWORDS: efﬁcacyguidelines;psychophysiologicalinterventions;treatmentoutcome;taskforceonefﬁcacy;
biofeedback.
PREAMBLE
ThechargetotheEfﬁcacyTemplateTaskForcerequiresthedevelopmentofatemplate
that will assist the Efﬁcacy and Practice Guideline Panels in their review of the literature
related to the clinical efﬁcacy of psychophysiological interventions. The Panels will be
requiredtouseacceptedscientiﬁcandclinicalstandardsfordeterminingwhetherabeneﬁcial
effectoftreatmentcanbedemonstrated.Thisdocumentisintendedasthetemplatethatwill
serve as a guideline for the Panels’ task. The ultimate goal is that of developing meaningful
efﬁcacy databases and practice guidelines for such interventions.
This task force was created as a collaborative effort by two professional societies (As-
sociation for Applied Psychophysiology and Biofeedback or AAPB; Society for Neuronal
Regulation or SNR) to assist in providing a systematic framework for comprehensiveness
and consistency in that endeavor. The guidelines that eventuate will, to the best extent
1Address all correspondence to Vincent J. Monastra, Attention Disorders Clinic, 2102 East Main Street, Endicott,
New York 13760; e-mail: poppidoc@aol.com.
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possible, recognize the interdisciplinary nature of clinical interventions and, to the best
extent possible, be developed by interdisciplinary panels and will be applicable to practi-
tioners from all disciplines. The practice guidelines that are developed from this template
are solely for the beneﬁt of the individuals who seek intervention and assistance, whether
theyarereferredtoaspatients,clients,or“consumers.”Theefﬁcacystatementsandpractice
guidelines that result from this template will be regarded as informational and educational
rather than as criteria for criticism.
PANEL PROCEDURES
Treatment guidelines that eventuate from this important process will greatly inﬂuence
the health and well being of consumers of the services. Determinations of efﬁcacy will be
undertakenwiththatheavyresponsibilityforemostinmind.Therefore,thepanelprocedures
will be open to public examination and members of the panels will be free of actual or
apparent conﬂict of professional or ﬁnancial interest.
Panel Membership
1. The Panels will be formed by the boards of the professional societies (AAPB and
SNR) responsible for creating and approving this template.
2. The Panels will reﬂect a range of disciplines with documented expertise regarding
deliveryoftheservicesunderconsideration,aswellasindividualswithexpertisein
the scientiﬁc and statistical methodology required to assess the intervention under
examination. The Panels may call upon consultants with expertise in other relevant
areas of efﬁcacy and clinical utility such as health-care economics, public health,
public service, and clinical guideline construction. The inclusion of a consumer
advocate familiar with the condition under examination may provide an invaluable
contribution.
3. All nominees for Panel membership or consultation will be required to fully dis-
close any potential or actual conﬂicts of interest, ﬁnancial or professional. Such
disclosures will be evaluated by bodies assigned to that responsibility.
4. ThePanelselectionandqualiﬁcationformembershipandthePanelproceduresand
decisionmakingprocesswillbeopentoexaminationbymembersofthesponsoring
professional organization(s).
Panel Process
1. Each Panel will ﬁrst deﬁne and agree upon their process and method, determining
the target condition, patient population, interventions to be included and/or ex-
cluded, provider type, and service settings. Other concerns, such as the diagnostic
speciﬁcity of the condition under consideration, may be included for review in the
process.
2. TimelinesforthePanelprocesswillbeestablishedindicatingapproximatelywhen
the report will be released for review.
3. Strategies for reviewing evidence will be explicitly outlined by each Panel. All
availabledataandevidencerelatedtothestatedgoal(s)ofthepanelwillbeavailableP1: FLT
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to the panel and reviewers. The Panels will document the “highest level of evi-
dence” available (i.e., randomized control trial, or RCT) and determine whether
there has been independent replication of the data.
4. Reports of adverse effects will be examined and included in the reports.
5. A full report will be prepared by each panel documenting its ﬁndings and recom-
mendations. The recommendations will be accompanied by documentation of the
rationale and level of evidence available for developing the recommendations.
6. Each Panel report will specify areas related to efﬁcacy and clinical utility that
require further research before adequate recommendations can be made.
7. The external validity of the recommendations will be kept in mind by the Panel.
Do the recommendations lead to improved therapeutic outcomes in the treatment
of the condition reviewed? The validity of the recommendations will be exam-
ined retrospectively by public consideration of the substance and quality of the
evidence cited.
8. Each Panel will make recommendations regarding the frequency with which the
recommendations and/or guidelines will be revised.
9. TheorganizationalPanelDevelopmentBoardsmaychoosetocreateapanelforthe
purpose of broadly addressing the effectiveness of psychophysiologically based
operant procedures in modifying autonomic activity, muscle activity, and brain-
waveactivity.Thesereviewscouldincludeevidencefromdifferentproblemareas.
10. Panel recommendations will be publicized for review and comment prior to being
formally adopted. Any concerns or comments will be fully and fairly considered
prior to adoption. Thus, from its inception, each Panel will function with the
awareness that the Panel processes will be open to review.
EFFICACY: HAVING THE DESIRED EFFECT
Overview
1. Thepurposeofoutcomeresearchmethodologyistoevaluatetheextenttowhichan
intervention can be regarded as efﬁcacious, and to evaluate the level of conﬁdence
professionals and consumers may place in such judgments. The efﬁcacy reports
and practice guidelines that result from the Panel activities will be based upon clin-
ical expertise and comprehensive and systematic analysis of research data, which
appears in peer-reviewed literature.
2. The ability to meaningfully assess outcome (efﬁcacy) studies assumes a basic
knowledge of clinical experimental design and analysis methods as well as eth-
ical standards for human research.
3. The ability to utilize practice guidelines assumes a fundamental level of training
andeducation,possessionofafoundationofrelevantknowledge,andeffectiveclin-
ical assessment skills that enable the clinical practitioner to set priorities and make
sound decisions regarding treatment method and focus. It is recognized that no set
of guidelines can be regarded as absolute criteria. When practice guidelines are de-
veloped, it will be recognized that at certain times clinical imperatives may require
a modiﬁcation of the “best practice” guidelines justiﬁed by a compelling profes-
sional rationale. The judgment of an experienced clinician is important, especially
when research data are limited.P1: FLT
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4. Technological and clinical advances sometimes occur at a rapid rate, so it will be
necessary to review the guidelines on a regular basis so they remain current and
relevant. Reviews will be updated at least every 3 years.
5. This document itself will be reviewed on a regular (annual) basis to determine
whether it provides adequate and effective guidance in light of changes that may
occur regarding treatment standards, diagnostic standards, ethical standards, or
research standards.
Scientiﬁc Considerations
Clinical psychophysiology uses variables that are quantiﬁable. The diagnostic criteria,
independent variables, dependent variables, and measurable intervening variables will be
included in the Panel deliberations. In methodological terms, the independent variables
are speciﬁc and subject to experimental manipulation (e.g., sensor placement, bandwidths
andfrequencies,reinforcementcontingencies).Thedependentvariables(e.g.,physiological
event being measured, response to treatment) can also be clearly speciﬁed. Often, interven-
ing variables (e.g., change in brainwave features, improved motor unit recruitment) can be
quantiﬁed.
1. The “condition of interest” (COI) will be clearly identiﬁed and operationally de-
ﬁned. Most often, the COI will be a diagnostic entity recognized in either the most
current Diagnostic and Statistical Manual (DSM) published by the American Psy-
chiatric Association, or in the most current International Classiﬁcation of Diseases
Handbook (ICD) published by the World Health Organization. If the COI is not a
recognized diagnostic entity but addresses symptomatic, cognitive, or behavioral
conditions (e.g., cognitive brightening, optimal functioning), the condition being
treated will be operationally deﬁned in a manner that permits objective assessment
and replication.
2. GuidelinesdevelopedbythePanelswillreﬂectthetechnicalfeaturesandparameters
of the particular treatment modality under review.
3. Panels will evaluate the extent to which reported interventions are amenable to
empirical analysis and replication by independent researchers.
4. If particular intervening variables (e.g., change in motor unit recruitment, shift
in brainwave frequencies) have been hypothesized to be relevant to the clini-
cal outcome, the Panel will evaluate the available empirical evidence for these
mechanisms.
5. Relevant variables such as age, gender, comorbidity, and treatment history will be
identiﬁed.
6. Outcome measures will be meaningfully related to the diagnostic criteria or COI
operational deﬁnition.
Speciﬁcity
WhiletheprimaryfunctionofthePanelsistoexamineevidenceforefﬁcacy,thePanels
will also examine whether treatment speciﬁcity has been demonstrated.P1: FLT
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1. Necessary or sufﬁcient treatment components: The primary function of the vari-
ous Panels is that of reviewing and reporting on evidence for treatment efﬁcacy.
Additionally, each Panel will report whether the study design permitted a determi-
nation as to whether a particular treatment component is necessary to the treatment
outcome, rather than just sufﬁcient to accomplish the treatment outcome. As an
example, it may be questioned whether the manipulation of a particular brainwave
frequency at a particular electrode location is necessary for successful treatment
outcome. Would the manipulation of a different brainwave frequency achieve the
same result? If not, then it would appear that manipulation of the particular fre-
quency is a necessary component of the treatment protocol. If a different frequency
serves as well, the variable may be sufﬁcient to produce change, but other variable
manipulations may facilitate symptomatic improvement as well. In that case, the
presenceofaparticularvariableintheclinicalprotocolmaybesufﬁcienttoproduce
a desired result, but it is not a necessary component. If that question is not tested in
the design, it cannot be assumed that the particular treatment variable is necessary
to the treatment outcome.
A particular aspect of the intervention (independent variable) may be nonspeciﬁc
as a component of the treatment protocol, but, at the same time, some element or
characteristicoftheclasstowhichthatindependentvariablebelongsmaybeneces-
sary to the desired outcome. For instance, a manipulation of a particular brainwave
frequency may not be necessary to the desired outcome, but the manipulation of at
least some brainwave frequency may be necessary to the desired outcome.
2. The Panel will determine whether “Placebo” nonspeciﬁcity can be ruled out as
the dominant effect. A more general concern about speciﬁcity is whether there is
simply some general characteristic of the treatment protocol that is responsible for
thedesiredchange.Inthatcase,noneoftheparticulartreatmentvariablesarereally
necessary for symptomatic improvement. Rather, simply participating in the study
and receiving empathy and encouragement from the therapist may be sufﬁcient
to produce symptomatic improvement. It is known that in some areas of applied
psychophysiology, very different protocols are reported to produce similar beneﬁ-
cial results. Thus, the protocols cannot be differentiated on the basis of outcome.
Similar problems are encountered in other therapies.2
Clinical Utility
Panels will recognize the distinction between “efﬁcacy” and “clinical utility” and
incorporate these distinctions into their deliberations and writings.
1. Efﬁcacy (having the desired effect) refers to the determination of treatment effect
derived from a systematic evaluation obtained in a controlled clinical trial.
2. Clinical utility refers to the practical value of an intervention, or the extent to
which it is practical and possible to translate the ﬁndings from efﬁcacy studies
2This is similar to the “Dodo Bird Verdict” resulting from studies of the efﬁcacy of different bona ﬁde psychother-
apies. It is suggested by some that available evidence supports the idea that all psychotherapies are nearly equal
in terms of efﬁcacy, see Wampold, D. E., Mondin, G.W., Moody, M., and Ahn, H. (1997). The ﬂat earth as a
metaphor for the evidence of uniform efﬁcacy of bona ﬁde psychotherapies: Reply to Crits-Christoph (1997) and
Howard et al. (1997). Psychological Bulletin, 122 (3): 226–230.P1: FLT
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into normal clinical practice. As an example, an intervention may be found to be
efﬁcacious, but meet such consumer resistance, require such expensive equipment
or extensive training to be implemented, or be so cost prohibitive that clinical
utility is compromised on a practical level. Additionally, a particular intervention
may be found to be efﬁcacious in a highly controlled study in which other factors
(comorbidity, treatment frequency, and so forth) are effectively controlled. The
sameprotocolmaybeineffectiveinthe“realworld”ofclinicalpracticewhenthose
variables are uncontrolled.
HIERARCHY OF EVIDENCE: CLINICAL TRIALS AND EFFICACY STUDIES
Treatmentefﬁcacyisdeterminedfromreportsofclinicaltrialsand/orcasestudies.The
scientiﬁcandclinicalcredibilityregardingtreatmentefﬁcacyderivesfromacombinationof
clinical experience and clinical trials. Interventions often begin as anecdotal reports or case
studies and ultimately are subject to formal and increasingly rigorous clinical trials, ﬁnally
tobeacceptedaseither“empiricallysupported”orrejectedasuseless.Theparticulardesign
and structure of the clinical trials and the number of independent replications are important
considerations for determining the degree to which a particular intervention can be claimed
tobeempiricallysupportedorempiricallyvalidated.Thereisagenerallyacceptedhierarchy
of “scientiﬁc power” for each clinical trial design.
1. Anecdotal evidence: This type of report is generally regarded as being without
scientiﬁc value, but is simply a narrative report about the observation that a par-
ticular treatment appears to have “worked.” Anecdotal reports cannot be used as
a basis for regarding a treatment as efﬁcacious by scientiﬁcally-minded health
care professionals, no matter how many anecdotal reports are identiﬁed. Anecdo-
tal reports may serve as a reason to examine the intervention in more controlled
settings.
2. UncontrolledCaseStudy:Thisisalsoquiteweak,scientiﬁcally.Agoodcasestudy
reportwillatleasthavethevirtueofclearspeciﬁcationoftherelevantindependent
and dependent variables that may assist in developing more effective controlled
studies.Casestudiesthatareregardedas“strong”willincludequantiﬁedpre–post
measures and, ideally, follow-up measures. A strong case report may be followed
by a series of case reports demonstrating positive outcome leading to controlled
clinical trials.
3. HistoricalControl:Thehistoricalcontrolassumesthatthecourseandnatureofthe
disorderordiseaseissowelldocumentedthataninterventionmaybedemonstrated
to be effective without the necessity of controls internal to the study. This is rarely
the case. An example of an effective historical control might be a disorder or
disease that is known to be so universally lethal (Ebola virus, hemorrhagic fever)
or debilitating (e.g., Alzheimer’s Disease) that any intervention that increases
survival rate or prolongs quality of life is regarded as efﬁcacious. Even then,
the intervention will be subjected to increasingly rigorous studies to identify the
effective independent and intervening variables.
4. ObservationalStudies:Retrospectiveorprospectivestudiesthatarecase-controlled
butnotrandomizedorblinded.Severalmetaanalysisstudieshavefoundthatthere
is no difference between case-controlled and prospective-randomized studies inP1: FLT
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terms of outcome, suggesting the validity of observational studies may approach
that of other designs that have either randomized or blinded assignment.3
5. Wait list or “intention to treat” controls: This is a frequent control design used
in clinical settings. Ideally, will participants be randomly assigned to wait list or
treatment conditions. It is a design that is intended to control for changes that may
be attributed to the natural course of the disorder, passage of time, self determined
“othertreatments,”participantexpectations,andsoforth.Participantsinthisstudy
receive the diagnostic evaluation both upon entry into the wait list group and after
a predetermined amount of time has passed, usually equal to the time required for
the investigational treatment to be accomplished. It is assumed that differences
between the wait list controls and investigational outcomes are attributable to
the investigational treatment variables. This design does not, however, control
for the ubiquitous presence of “nonspeciﬁc variables” that are present in every
clinical study of an investigational treatment, nor does it control for experimenter
bias. There is some concern that merely participating in the initial diagnostic
procedures may alter the repeated measures in the absence of any intervention. In
a clinical setting, there may be ethical concerns about randomization into wait list
ortreatmentconditionsbasedupontheprinciplethattheresearcherhasdetermined
who will receive treatment and who will be deferred. Informed consent becomes
critical.
6. Within-subject and intrasubject replication designs. The most common example
of this is the “A–B–A” design. This design can be a powerful demonstration of
the speciﬁcity of the investigational independent variable. It does not, however,
control for experimenter bias unless the clinician is “blind” to the reversal contin-
gencies.Theremaybeethicalconcernsinherentinpurposelyattemptingtodemon-
strate symptom reversal in the “B” condition for the sole purpose of experimental
manipulation.
7. Single blind, random assignment control design, either sham or active (behav-
ioral,psychological,orpharmacological)treatmentcontrols:Thisdesign“blinds”
the subject to the particular treatment condition to which they have been as-
signed, thus controlling for some of the nonspeciﬁc subject variables that may
operate in the study (expectancy, acquiescent response bias, etc.). It does not
control for experimenter bias. Again, there may be ethical considerations in the
use of sham treatment controls if known and effective treatments are already
available. This will be brieﬂy discussed later. There are also signiﬁcant statisti-
cal issues associated with the active treatment control design that the panel will
consider.
8. Double blind control studies, sham or active controls, random assignment: This
design “blinds” both the subject and the experimenter to the treatment condition,
thuscontrollingforbothsubjectvariablesandexperimenterbias.Thedoubleblind
sham controlled design is considered, from a purely scientiﬁc perspective, to be
the sine qua non of clinical trial designs, although some have argued in favor of
3While the use of randomized, controlled group designs enables a clinical researcher to control for certain sources
of experimental “error,” it is erroneous to conclude that well-designed, case-controlled studies are of limited
value. See Benson and Hartz (2000) for a comprehensive review of this topic.P1: FLT
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the double blind design, which contains both active and sham controls as well as
the investigational condition.
9. Treatment Equivalence or Treatment Superiority Designs: This design compares
the investigational treatment to a known and accepted standard treatment.
The ethical issue of a “no treatment” control is circumvented, but other de-
sign and analysis issues arise related to “assay sensitivity.” The standard
treatment will have a known placebo response proﬁle for the COI. A de-
monstration of “equivalence” may not be meaningful if the study is poorly ac-
complished or if the standard does not “separate” from placebo or sham
effectively.
10. Other Designs: Other more sophisticated clinical trial designs (Double Dummy,
Solomon Four Group) are available, but will not be treated here. The panel
will be prepared to evaluate each clinical trial report individually and as part
of a “meta-analysis” in reaching a conclusion about the degree to which the
intervention is empirically supported as an intervention for a particular
COI.
CRITERIA FOR LEVELS OF EVIDENCE OF EFFICACY
Level1:Supportedonlybyanecdotalreportsand/orcasestudiesinnonpeerreviewedvenues.
Not empirically supported.
Level 2: Possibly Efﬁcacious. At least one study of sufﬁcient statistical power with well
identiﬁed outcome measures, but lacking randomized assignment to a control condition
internal to the study.
Level 3: Probably Efﬁcacious. Multiple observational studies, clinical studies, wait list con-
trolled studies, and within-subject and intrasubject replication studies that demonstrate
efﬁcacy.
Level 4: Efﬁcacious:
(a) In a comparison with a no-treatment control group, alternative treatment group,
or sham (placebo) control utilizing randomized assignment, the investigational
treatment is shown to be statistically signiﬁcantly superior to the control condition
or the investigational treatment is equivalent to a treatment of established efﬁcacy
in a study with sufﬁcient power to detect moderate differences,
(b) The studies have been conducted with a population treated for a speciﬁc prob-
lem, for whom inclusion criteria are delineated in a reliable, operationally deﬁned
manner,
(c) Thestudyusedvalidandclearlyspeciﬁedoutcomemeasuresrelatedtotheproblem
being treated,
(d) The data are subjected to appropriate data analysis,
(e) The diagnostic and treatment variables and procedures are clearly deﬁned in a
manner that permits replication of the study by independent researchers, and
(f) The superiority or equivalence of the investigational treatment have been shown
in at least two independent research settings.
Level 5: Efﬁcacious and Speciﬁc. The investigational treatment has been shown to be
statistically superior to credible sham therapy, pill, or alternative bona ﬁde treatment in
at least two independent research settings.P1: FLT
Applied Psychophysiology and Biofeedback [apb] pp646-apbi-453362 November 6, 2002 11:44 Style ﬁle version June 4th, 2002
Guidelines for Evaluation of Clinical Efﬁcacy of Psychophysiological Interventions 281
OTHER CONSIDERATIONS THAT CONTRIBUTE TO CONFIDENCE
IN STUDIES EFFICACY
1. Outcome measures will be relevant to the disorder as diagnosed or operationally
deﬁned. Studies using multiple outcome measures are considered to be stronger
demonstrations of efﬁcacy than studies using single outcome measures.
2. Measures of any changes in life functioning, such as occupational, social, family
function, and subjective well being will be evaluated by the panel.
3. Iatrogenic complications reported in the literature will be reported by the Panel.
4. The Panel will differentiate between measures that produce mere statistical signif-
icance vs. those that also produce demonstrable clinically signiﬁcant changes.
5. As discussed earlier, the intervention variables will be reported in sufﬁcient detail
that the procedure could be replicated consistently across clinical settings.
6. The Panel will examine “intent to treat” data specifying attrition because of drop
out or refusal.
7. Ultimately, there will be long-term follow-up studies of the intervention effects.
8. Replication, using appropriate designs and analysis, by two or more independent
sites contributes signiﬁcantly to the credibility of the reports. While randomized
assignment to treatment conditions may represent the currently accepted scientiﬁc
ideal,recentmeta-analyseshaveindicatedthatnon-randomizedobservationalstud-
iescanproducesimilarresults(Benson&Hartz,2000;Brittonetal.,1998;Concato,
Shah, & Horwitz, 2000)
ETHICAL STANDARDS FOR RESEARCH
The panels will examine the research reports in light of published ethical standards
governing human subject research. Two well-known documents are the Declaration of
Helsinki, published by the World Medical Association (2000), and the Belmont Report
(1979), published by the Department of Health and Human Services. Ethically critical
issues such as informed consent, protections for vulnerable populations (e.g., children,
developmentally disabled, cognitively impaired, severe psychopathology), and appropriate
use of placebo or sham controls will be examined. The ﬁnal reports will discuss, in a
general sense, any ethical lapses or problems identiﬁed. Studies may be scientiﬁcally sound
but ethically unacceptable.
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